SEHK:867Pharmaceuticals
China Medical System Holdings (SEHK:867) Valuation After siRNA Obesity Therapy Trial Approval
China Medical System Holdings (SEHK:867) has received National Medical Products Administration approval to begin clinical trials for CMS-D008, an siRNA therapy targeting INHBE in overweight and obese individuals and using a mechanism that is different from GLP-1RAs.
See our latest analysis for China Medical System Holdings.
The CMS-D008 trial approval lands after a choppy stretch for the shares, with a 7 day share price return of 11.14% decline and a 30 day share price return of 10.22%...